Exclusive Online Content
Passage Bio Launches With $115.5 Million Financing to Develop AAV-Delivered Therapeutics
Passage Bio recently debuted with a $115.-million Series A financing led by OrbiMed Advisors and joined by Frazier Healthcare Partners, Versant Ventures, New Leaf Venture Partners, Vivo Capital and Lilly Asia Ventures.
DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical
DiaMedica Therapeutics Inc. recently announced it has initiated dosing patients with chronic kidney disease (CKD) in a Phase Ib clinical study evaluating DM199.
Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License: Triggers Milestone
Codexis, Inc. recently announced that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialization of Codexis’ novel, orally delivered enzyme CDX-6114 for the management of phenylketonuria (PKU), an orphan metabolic disorder.
West Annouces Significant Agreements With Swissfillon & scPharmaceuticals
West recently announced it has commenced discussions with two companies regarding the use of West’s proprietary SmartDose drug delivery platform for complex molecules.
uniQure Announces First Patient Treated in Pivotal Trial
uniQure N.V. recently announced it treated the first patient in its HOPE-B pivotal trial of AMT-061, an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B.
Meridian Launches New Range of Lyo-Ready PCR Mixes
Meridian Bioscience, Inc. recently announced that following the successful release of the Lyo-Ready qPCR Mix, Meridian is proud to introduce its next-generation lyophilization-ready mixes for one-step RT-qPCR.
ABITEC Corporation Launches New Versatile Excipient for Oral Dose Applications
ABITEC Corporation, a global manufacturer of specialty lipids, continues to develop products that meet the ever-evolving demands of the pharmaceutical industry.
PCI Pharma Services Announces Bottling Line Expansion to Support Customer Needs
PCI Pharma Services recently announce the expansion of its bottling line capacity at its Commercial Packaging site in Rockford, IL.
AbbVie’s Immunology Pipeline Will Protect it From Biosimilar Erosion
Although AbbVie is feeling the impact of Humira biosimilar launch in Europe, its strong immunology pipeline is likely to protect its hold on the plaque psoriasis (PsO) and rheumatoid arthritis (RA) markets, according to GlobalData, a leading data and analytics company.
First Oral Add-On Treatment to Insulin for Treatment of Certain Patients With Type 1 Diabetes
The EMA’s human medicines committee (CHMP) has recommended for the first time an adjunct treatment to insulin in the form of a tablet for certain patients with type 1 diabetes mellitus.
EXCLUSIVE ONLINE CONTENT
Passage Bio Launches With $115.5 Million Financing to Develop AAV-Delivered Therapeutics
Passage Bio recently debuted with a $115.-million Series A financing led by OrbiMed Advisors and joined by Frazier Healthcare Partners, Versant Ventures, New Leaf Venture Partners, Vivo Capital and Lilly Asia Ventures.
DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical
DiaMedica Therapeutics Inc. recently announced it has initiated dosing patients with chronic kidney disease (CKD) in a Phase Ib clinical study evaluating DM199.
Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License: Triggers Milestone
Codexis, Inc. recently announced that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialization of Codexis’ novel, orally delivered enzyme CDX-6114 for the management of phenylketonuria (PKU), an orphan metabolic disorder.
West Annouces Significant Agreements With Swissfillon & scPharmaceuticals
West recently announced it has commenced discussions with two companies regarding the use of West’s proprietary SmartDose drug delivery platform for complex molecules.
uniQure Announces First Patient Treated in Pivotal Trial
uniQure N.V. recently announced it treated the first patient in its HOPE-B pivotal trial of AMT-061, an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B.